Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Restructuring (2016 - 2017)

Altimmune (ALT) has disclosed Cash from Restructuring for 3 consecutive years, with -$66633.0 as the latest value for Q1 2017.

  • Quarterly Cash from Restructuring rose 66.13% to -$66633.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was -$267300.0 through Mar 2017, up 83.35% year-over-year, with the annual reading at -$397383.0 for FY2016, 182.49% down from the prior year.
  • Cash from Restructuring for Q1 2017 was -$66633.0 at Altimmune, roughly flat from -$66633.0 in the prior quarter.
  • The five-year high for Cash from Restructuring was $1.9 million in Q1 2015, with the low at -$1.1 million in Q2 2015.
  • Average Cash from Restructuring over 3 years is $7306.6, with a median of -$66727.0 recorded in 2016.
  • Peak annual rise in Cash from Restructuring hit 93.93% in 2016, while the deepest fall reached 762.99% in 2016.
  • Over 3 years, Cash from Restructuring stood at -$319008.0 in 2015, then skyrocketed by 79.11% to -$66633.0 in 2016, then changed by 0.0% to -$66633.0 in 2017.
  • According to Business Quant data, Cash from Restructuring over the past three periods came in at -$66633.0, -$66633.0, and -$67307.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.